A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy. Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins…